vs
Side-by-side financial comparison of JOINT Corp (JYNT) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
JOINT Corp is the larger business by last-quarter revenue ($15.2M vs $13.7M, roughly 1.1× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 6.5%, a 69.2% gap on every dollar of revenue. JOINT Corp produced more free cash flow last quarter ($334.7K vs $-2.1M).
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
JYNT vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.2M | $13.7M |
| Net Profit | $991.1K | $10.4M |
| Gross Margin | 81.4% | — |
| Operating Margin | 4.9% | -86.5% |
| Net Margin | 6.5% | 75.7% |
| Revenue YoY | 3.1% | — |
| Net Profit YoY | 5510.5% | 179.1% |
| EPS (diluted) | $0.06 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.2M | $13.7M | ||
| Q3 25 | $13.4M | $19.1M | ||
| Q2 25 | $13.3M | $8.1M | ||
| Q1 25 | $13.1M | $2.9M | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | $30.2M | — | ||
| Q2 24 | $30.3M | — | ||
| Q1 24 | $29.7M | — |
| Q4 25 | $991.1K | $10.4M | ||
| Q3 25 | $855.0K | $-16.3M | ||
| Q2 25 | $93.4K | $-15.8M | ||
| Q1 25 | $967.8K | $-13.3M | ||
| Q4 24 | $17.7K | — | ||
| Q3 24 | $-3.2M | — | ||
| Q2 24 | $-3.6M | — | ||
| Q1 24 | $947.0K | — |
| Q4 25 | 81.4% | — | ||
| Q3 25 | 80.1% | — | ||
| Q2 25 | 79.1% | — | ||
| Q1 25 | 77.3% | — | ||
| Q4 24 | 78.4% | — | ||
| Q3 24 | 90.7% | — | ||
| Q2 24 | 90.7% | — | ||
| Q1 24 | 90.9% | — |
| Q4 25 | 4.9% | -86.5% | ||
| Q3 25 | 1.2% | -10.1% | ||
| Q2 25 | -8.6% | -177.7% | ||
| Q1 25 | -5.2% | -472.7% | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | -1.6% | — | ||
| Q2 24 | -5.9% | — | ||
| Q1 24 | -1.4% | — |
| Q4 25 | 6.5% | 75.7% | ||
| Q3 25 | 6.4% | -85.4% | ||
| Q2 25 | 0.7% | -196.0% | ||
| Q1 25 | 7.4% | -452.7% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | -10.5% | — | ||
| Q2 24 | -11.9% | — | ||
| Q1 24 | 3.2% | — |
| Q4 25 | $0.06 | $-3.74 | ||
| Q3 25 | $0.06 | $-0.11 | ||
| Q2 25 | $0.01 | $-0.16 | ||
| Q1 25 | $0.06 | $-0.18 | ||
| Q4 24 | $0.01 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.24 | — | ||
| Q1 24 | $0.06 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.6M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.1M | $35.3M |
| Total Assets | $61.0M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.6M | $137.5M | ||
| Q3 25 | $29.7M | $103.8M | ||
| Q2 25 | $29.8M | $121.6M | ||
| Q1 25 | $21.9M | $89.1M | ||
| Q4 24 | $25.1M | — | ||
| Q3 24 | $20.7M | — | ||
| Q2 24 | $17.5M | — | ||
| Q1 24 | $18.7M | — |
| Q4 25 | $15.1M | $35.3M | ||
| Q3 25 | $22.7M | $-8.1M | ||
| Q2 25 | $23.2M | $7.1M | ||
| Q1 25 | $22.8M | $10.7M | ||
| Q4 24 | $20.7M | — | ||
| Q3 24 | $20.5M | — | ||
| Q2 24 | $23.2M | — | ||
| Q1 24 | $26.2M | — |
| Q4 25 | $61.0M | $154.7M | ||
| Q3 25 | $69.4M | $133.7M | ||
| Q2 25 | $73.2M | $133.8M | ||
| Q1 25 | $80.1M | $103.7M | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $79.6M | — | ||
| Q2 24 | $82.4M | — | ||
| Q1 24 | $85.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-2.0M |
| Free Cash FlowOCF − Capex | $334.7K | $-2.1M |
| FCF MarginFCF / Revenue | 2.2% | -15.3% |
| Capex IntensityCapex / Revenue | 9.9% | 0.7% |
| Cash ConversionOCF / Net Profit | 1.86× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $-2.0M | ||
| Q3 25 | $1.8M | $-17.5M | ||
| Q2 25 | $868.6K | $-14.5M | ||
| Q1 25 | $-3.7M | $29.0M | ||
| Q4 24 | $9.4M | — | ||
| Q3 24 | $3.4M | — | ||
| Q2 24 | $-973.5K | — | ||
| Q1 24 | $2.8M | — |
| Q4 25 | $334.7K | $-2.1M | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $363.6K | $-14.9M | ||
| Q1 25 | $-4.0M | $29.0M | ||
| Q4 24 | $8.2M | — | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $-1.2M | — | ||
| Q1 24 | $2.4M | — |
| Q4 25 | 2.2% | -15.3% | ||
| Q3 25 | 10.9% | — | ||
| Q2 25 | 2.7% | -184.0% | ||
| Q1 25 | -30.8% | 988.3% | ||
| Q4 24 | 55.9% | — | ||
| Q3 24 | 10.6% | — | ||
| Q2 24 | -4.1% | — | ||
| Q1 24 | 8.1% | — |
| Q4 25 | 9.9% | 0.7% | ||
| Q3 25 | 2.4% | 0.0% | ||
| Q2 25 | 3.8% | 5.0% | ||
| Q1 25 | 2.5% | 0.8% | ||
| Q4 24 | 8.1% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | 1.86× | -0.19× | ||
| Q3 25 | 2.07× | — | ||
| Q2 25 | 9.30× | — | ||
| Q1 25 | -3.82× | — | ||
| Q4 24 | 532.98× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.97× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
XLO
Segment breakdown not available.
